1. Targeting tryptophan availability to tumors: the answer to immune escape?
    Abdulla A-B Badawy, 2018, Immunol Cell Biol CrossRef
  2. The Role of Poly(ADP-Ribose) Polymerase-1 in Cutaneous Wound Healing
    Jaideep Banerjee et al, 2019, Advances in Wound Care CrossRef
  3. Nicotinamide induces mitochondrial-mediated apoptosis through oxidative stress in human cervical cancer HeLa cells
    Yi Feng et al, 2017, Life Sciences CrossRef
  4. The Role of Nicotinamide in Cancer Chemoprevention and Therapy
    Ilias P. Nikas et al, 2020, Biomolecules CrossRef
  5. Possible mechanisms of cancer prevention by nicotinamide
    Aitziber Buqué et al, 2020, Br J Pharmacol CrossRef
  6. Autophagy-Inducing Inhalable Co-crystal Formulation of Niclosamide-Nicotinamide for Lung Cancer Therapy
    Eupa Ray et al, 2020, AAPS PharmSciTech CrossRef
  7. Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide
    Abdulla A.-B. Badawy, 2020 CrossRef
  8. Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice
    Benson Chellakkan Selvanesan et al, 2020, J Immunother Cancer CrossRef
  9. Poly(ADP-ribose) Glycohydrolase Inhibition Sequesters NAD+ to Potentiate the Metabolic Lethality of Alkylating Chemotherapy in IDH-Mutant Tumor Cells
    Hiroaki Nagashima et al, 2020, Cancer Discov CrossRef
  10. NNMT Silencing Activates Tumor Suppressor PP2A, Inactivates Oncogenic STKs, and Inhibits Tumor Forming Ability
    Kamalakannan Palanichamy et al, 2017, Clin Cancer Res CrossRef
  11. Modulating the Radiation Response for Improved Outcomes in Breast Cancer.
    Andrea M Pesch et al, 2021, JCO Precis Oncol CrossRef
  12. Pharmacological inhibition of tumor anabolism and host catabolism as a cancer therapy
    Alejandro Schcolnik-Cabrera et al, 2021, Sci Rep CrossRef
  13. Post-chemotherapy maintenance treatment by nicotinamide riboside, a poly ADP ribose polymerase 1 inhibitor, in BRCA mutated advanced ovarian cancer – A perspective
    Mukul Arvind Gharote et al, 2021, IJMIO CrossRef
  14. Nicotinamide (niacin) supplement increases lipid metabolism and ROS‐induced energy disruption in triple‐negative breast cancer: potential for drug repositioning as an anti‐tumor agent
    Minsun Jung et al, 2022, Molecular Oncology CrossRef
  15. Improved delivery of Mcl-1 and survivin siRNA combination in breast cancer cells with additive siRNA complexes
    Tinnabhop Santadkha et al, 2022, Invest New Drugs CrossRef
  16. Endogenous metabolism in endothelial and immune cells generates most of the tissue vitamin B3 (nicotinamide)
    Julianna D. Zeidler et al, 2022, iScience CrossRef
  17. Comprehensive analysis of nicotinamide metabolism-related signature for predicting prognosis and immunotherapy response in breast cancer
    Hanxiao Cui et al, 2023, Front. Immunol. CrossRef
  18. DNA Repair and Therapeutic Strategies in Cancer Stem Cells
    Matthew S. Gillespie et al, 2023, Cancers CrossRef
  19. Endogenous Metabolism in Endothelial and Immune Cells Is the Main Source of Tissue Levels of the Vitamin B 3 Nicotinamide
    Julianna D. Zeidler et al, 2022, SSRN Journal CrossRef
  20. Valproic acid reprograms the metabolic aberration of cisplatin treatment via ALDH modulation in triple-negative breast cancer cells
    Avital Granit Mizrahi et al, 2023, Front. Cell Dev. Biol. CrossRef
  21. Spectroscopic, quantum computational, topological, Fukui functions and molecular docking analysis on a potential anti-cancer molecule Nicotinamide by DFT method
    K. Rajkumar et al, 2023, Journal of Molecular Structure CrossRef
  22. High-dose nicotinamide, a histone deacetylase inhibitor (Sirtuin-1), can prevent emergence of treatment resistance in chronic myeloid leukemia – A perspective
    Mukul Arvind Gharote, 2024, IJMIO CrossRef
  23. Current Trends in Sirtuin Activator and Inhibitor Development.
    Karina L Bursch et al, 2024, Molecules CrossRef